36 completed, 14 terminated, 3 withdrawn. 31 Phase 1, 24 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 31 | Completed 21, Terminated 8, Withdrawn 2 |
| Phase 2 | 24 | Completed 17, Terminated 5, Withdrawn 2 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow tanespimycin: new trials by email Literature Review of tanespimycin trials Research Report on tanespimycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies ABI-010 - Solid Tumor | Phase 1 | Withdrawn | Celgene | 2012-04-01 | 2018-04-11 | |
| Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer IPI-504, Everolimus - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 47 | 2011-07-01 | 2014-11-13 |
| A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer IPI 504 plus Docetaxel, Placebo plus Docetaxel - Non Small Cell Lung Cancer | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 226 | 2011-05-01 | 2014-05-19 |
| IPI-504 in NSCLC Patients With ALK Translocations IPI-504 - Lung Cancer, Stage IIIb Lung Cancer | Phase 2 | Terminated | Massachusetts General Hospital | 3 | 2010-10-01 | 2017-12-04 |
| Dose Escalation of IPI-493 in Hematologic Malignancies IPI-493 - Hematologic Malignancies | Phase 1 | Terminated | Infinity Pharmaceuticals, Inc. | 4 | 2010-06-01 | 2015-04-15 |
| Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma IPI-504 - Dedifferentiated Liposarcoma | Phase 2 | Withdrawn | Infinity Pharmaceuticals, Inc. | 2010-01-01 | 2015-04-14 | |
| Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer IPI-504, Trastuzumab - Breast Cancer, HER2 Positive Breast Cancer | Phase 2 | Terminated | Infinity Pharmaceuticals, Inc. | 29 | 2009-03-01 | 2012-12-11 |
| Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib retaspimycin hydrochloride (IPI-504), placebo, Best supportive care - Gastrointestinal Stromal Tumors | Phase 3 | Terminated | Infinity Pharmaceuticals, Inc. | 47 | 2008-08-01 | 2012-12-11 |
| A Phase 1 Dose Escalation Study of IPI-493 IPI-493 - Advanced Malignancies | Phase 1 | Terminated | Infinity Pharmaceuticals, Inc. | 53 | 2008-07-01 | 2015-04-15 |
| A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer IPI-504 - Breast Cancer | Phase 1 / Phase 2 | Withdrawn | MedImmune LLC | 56 | 2008-04-01 | 2010-02-03 |
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer gemcitabine hydrochloride, tanespimycin - Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2008-03-01 | 2014-07-25 |
| A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse Tanespimycin, Bortezomib - Multiple Myeloma | Phase 3 | Completed | Bristol-Myers Squibb | 31 | 2008-02-01 | 2011-06-28 |
| A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma IPI-504 - Metastatic Melanoma | Phase 2 | Terminated | Infinity Pharmaceuticals, Inc. | 1 | 2008-02-01 | 2012-12-10 |
| Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors IPI-504, docetaxel - Solid Tumors | Phase 1 | Completed | Infinity Pharmaceuticals, Inc. | 60 | 2007-12-01 | 2012-03-06 |
| A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer IPI-504 - Prostate Cancer, Prostatic Neoplasms | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 19 | 2007-11-01 | 2012-12-11 |
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer gemcitabine hydrochloride, tanespimycin - Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 29 | 2007-10-01 | 2014-05-20 |
| A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma tanespimycin, Bortezomib - Multiple Myeloma | Phase 2 / Phase 3 | Completed | Bristol-Myers Squibb | 22 | 2007-08-01 | 2015-12-07 |
| Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) IPI-504 - Lung Cancer | Phase 1 / Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 88 | 2007-01-01 | 2012-12-10 |
| Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin Tanespimycin - Advanced Malignancies | Phase 2 | Completed | Bristol-Myers Squibb | 6 | 2006-07-01 | 2015-10-12 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis tanespimycin - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 37 | 2006-05-01 | 2012-03-15 |
Showing 20 of 53. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Leukemia, Lymphocytic, Chronic, B-Cell (10) · Lymphoma, Mantle-Cell (8) · Lymphoma, B-Cell, Marginal Zone (7) · Lymphoma, Follicular (7) · Lymphoma, Large B-Cell, Diffuse (7) · Burkitt Lymphoma (6) · Hodgkin Disease (6) · Lymphoma, Large-Cell, Immunoblastic (6) · Lymphoma, Non-Hodgkin (6) · Breast Neoplasms (5) · Lymphoma, Large-Cell, Anaplastic (5) · Lymphoma, T-Cell, Cutaneous (5) · Mycosis Fungoides (5) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (5)
National Cancer Institute (NCI) (24) · Infinity Pharmaceuticals, Inc. (13) · Bristol-Myers Squibb (4) · Cancer Research UK (2) · Memorial Sloan Kettering Cancer Center (2) · Barbara Ann Karmanos Cancer Institute (1) · Biogen (1) · Celgene (1) · Jonsson Comprehensive Cancer Center (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · MedImmune LLC (1) · National Institutes of Health Clinical Center (CC) (1)
United States (50) · Canada (2) · United Kingdom (2) · Hungary (1) · Romania (1) · Russia (1) · South Korea (1) · Spain (1) · Taiwan (1)
Charles Erlichman (2) · Pedro Santabarbara, M.D. (2) · Anas Younes (1) · Antonio T. Fojo, MD, PhD (1) · Archie Tse (1) · Brenda Weigel (1) · Charles A. Schiffer, MD (1) · Charles Erlichman, MD (1) · Charles Sawyers, MD (1) · David E. Weng, M.D., PhD (1) · David S. Siegel, MD; Ph.D (1) · David Solit (1) · Elaina Gartner (1) · Elisabeth Heath (1)
PMID 15961763, PMID 16832603, PMID 20683637, PMID 21791475, PMID 23256542, PMID 23887852
U01CA069912 (5), P30CA015083 (4), N01CM62205 (3), U01CA062487 (3), U01CA069856 (3), P30CA022453 (2), U01CA062502 (2), U01CA099168 (2), N01CM17104 (1), N01CM62206 (1), N01CM62207 (1), P30CA008748 (1), P30CA016672 (1), R21CA115048 (1), R21CA117070 (1)